Share on LinkedInShare on LinkedIn

ARTICLE · 26 MAY 2020

Compulsory Or Not? Licensing During The Covid-19 Pandemic

The compulsory licensing discussion continues to be one of the hot topics in IP world after the announcement of the Covid-19 pandemic by World Health Organization (WHO).

TurkeyIntellectual Property

The compulsory licensing discussion continues to be one of the hot topics in IP world after the announcement of the Covid-19 pandemic by World Health Organization (WHO).

Several countries such as France, Germany, Canada amended or passed new legislation with an attempt to provide the possibility of compulsory licensing as a part of the measures with the Covid-19 pandemic.

Israel was the first Country to approve a compulsory license for the importation of the generics of AbbVie's patented Kaletra® medicine from India for use in the treatment of Covid-19 disease.  AbbVie however announced that it will not enforce its patent rights for Kaletra® medicine.

Gilead, a research-based biopharmaceutical company, announced that it will rescind its Remdesivir orphan drug designation before the Food and Drug Administration (FDA).

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

See more popular content from